alarm Free 2 Day Shipping over $49
Questions? 1 (844) 844 0031
click subdirectory_arrow_left
10
%
OFF
On Your
First Order
25
%
OFF
On Your
First Order
25
%
OFF
On Your
First Order
Click to open
expanded view

Depo-Medrol

For the treatment of inflammatory, allergic & musculoskeletal conditions

Species: Dog Cat Horse
Prescription required
Strength:
FREE shipping over $49
Ships Free!

Depo-Medrol

For the treatment of inflammatory, allergic & musculoskeletal conditions

Species: Dog Cat Horse
Prescription required
Strength:
FREE shipping over $49
Ships Free!
Product images:

Product description

Depo-Medrol is a sterile aqueous suspension for injection for the treatment of inflammatory, allergic and musculoskeletal conditions in cats, dogs and horses.

Active ingredients

  • Each ml of Depo-Medrol contains:
Name Methylprednisolone acetate Polyethylene glycol 3350 Sodium chloride Myristyl-gamma-picolinium chloride added as preservative
Depo-Medrol 20mg/ml 20mg 29.6mg 8.9mg 0.198 mg
Depo-Medrol 40mg/ml 40mg 29mg 8.7mg 0.195 mg
  • When necessary, pH was adjusted with sodium hydroxide and/or hydrochloric acid.

Indications for use

  • Musculoskeletal Condition:

    • As with other adrenal steroids, Depo-Medrol has been found useful in alleviating the pain and lameness associated with acute localized arthritic conditions and generalized arthritic conditions. It has been used successfully to treat rheumatoid arthritis, traumatic arthritis, osteoarthritis, periostitis, tendinitis, synovitis, tenosynovitis, bursitis, and myositis of horses; traumatic arthritis, osteoarthritis, and generalized arthritic conditions of dogs. Remission of musculoskeletal conditions may be permanent, or symptoms may recur, depending on the cause and extent of structural degeneration.
  • Allergic Conditions:

    • This preparation is especially beneficial in relieving pruritus and inflammation of allergic dermatitis, acute moist dermatitis, dry eczema, urticaria, bronchial asthma, pollen sensitivities and otitis externa in dogs; allergic dermatitis and moist and dry eczema in cats. Onset of relief may begin within a few hours to a few days following injection and may persist for a few days to six weeks. Symptoms may be expected to recur if the cause of the allergic reaction is still present, in which case retreatment may be indicated.
  • Other Conditions:

    • In certain conditions where it is desired to reduce inflammation, vascularization, fibroblastic infiltration, and scar tissue, the use of Depo-Medrol should be considered. Snakebite of dogs also is an indication for the use of this suspension because of its anti-toxemic, anti-shock, and anti-inflammatory activity. It is particularly effective in reducing swelling and preventing sloughing. Its employment in the treatment of such conditions is recommended as a supportive measure to standard procedures and time-honored treatments and will give comfort to the animal and hasten complete recovery.

Administration and dosage

Depo-Medrol instramuscular administration:

  • Following intramuscular injection of methylprednisolone acetate, a prolonged systemic effect results. The dose varies with the size of the animal patient, the severity of the condition under treatment, and the animal’s response to therapy.

Cats and dogs:

  • The average intramuscular dose for dogs is 20 mg. In accordance with the size of the dog and severity of the condition under treatment, the dose may range from 2 mg in miniature breeds to 40 mg in medium breeds, and even as high as 120 mg in extremely large breeds or dogs with severe involvement.
  • The average intramuscular dose for cats is 10 mg with a range up to 20 mg. Injections may be made at weekly intervals or in accordance with the severity of the condition and clinical response

Horses:

  • The usual intramuscular dose for horses is 200 mg repeated as necessary. For maintenance therapy in chronic conditions, initial doses should be reduced gradually until the smallest effective (ie, individualized) dose is established.
  • When treatment is to be withdrawn after prolonged and intensive therapy, the dose should be reduced gradually.

Depo-Medrol intrasynovial administration:

  • Methylprednisolone acetate, a slightly soluble ester of methylprednisolone, is capable of producing a more prolonged local anti-inflammatory effect than equimolar doses of hydrocortisone acetate.

    • Following intrasynovial injection, relief from pain may be experienced within 12 to 24 hours. The duration of relief varies, but averages three to four weeks, with a range of one to five or more weeks. Injections of methylprednisolone acetate have been well tolerated. Intrasynovial (intra-articular) injections may occasionally result in an increased localized inflammatory response.
  • Intrasynovial injection is recommended as an adjuvant to general therapeutic measures to effect suppression of inflammation in one or a few peripheral structures when:

    • The disease is limited to one or a few peripheral structures.
    • The disease is widespread with one or a few peripheral structures actively inflamed.
    • Systemic therapy with other corticoids or corticotropin controls all but a few of the more actively involved structures.
    • Systemic therapy with cortisone, hydrocortisone, or corticotropin is contraindicated.
    • Joints show early but actively progressing deformity (to enhance the effect of physiotherapy and corrective procedures).
    • Surgical or other orthopedic corrective measures are to be or have been done.
  • Procedure for Intrasynovial Injection:

    • The anatomy of the area to be injected should be reviewed in order to assure that the suspension is properly placed and to determine that large blood vessels or nerves are avoided. The injection site is located where the synovial cavity is most superficial. The area is prepared for aseptic injection of the medicament by the removal of hair and cleansing of the skin with alcohol.

    • A sterile 18- to 21-gauge needle for horses, 20- to 22-gauge needle for dogs, on a dry syringe is quickly inserted into the synovial space and a small amount of synovial fluid withdrawn. If there is an excess of synovia and more than 1 mL of suspension is to be injected, it is well to aspirate a volume of fluid comparable to that which is to be injected.

    • With the needle in place, the aspirating syringe is removed and replaced by a second syringe containing the proper amount of suspension which is then injected. In some animals a transient pain is elicited immediately upon injection into the affected cavity. This pain varies from mild to severe and may last for a few minutes up to 12 hours. After injection, the structure may be moved gently a few times to aid mixing of the synovial fluid and the suspension. The site may be covered with a small sterile dressing.

    • Areas not suitable for injection are those that are anatomically inaccessible such as spinal joints and those like the sacroiliac joints, which are devoid of synovial space. Treatment failures are most frequently the result of failure to enter the synovial space. If failures occur when injections into the synovial spaces are certain, as determined by aspiration of fluid, repeated injections are usually futile. Local therapy does not alter the underlying disease process, and whenever possible comprehensive therapy including physiotherapy and orthopedic correction should be employed. The single intrasynovial dose depends on the size of the part, which corresponds to the size of the animal. The interval between repeated injections depends on the duration of relief obtained

Horses:

  • The average initial dose for a large synovial space in horses is 120 mg with a range from 40 to 240 mg. Smaller spaces will require a correspondingly lesser dose.

Dogs:

  • The average initial dose for a large synovial space in dogs is 20 mg. Smaller spaces will require a correspondingly lesser dose.

Prescribing information

picture_as_pdf Depo-Medrol